Treatment of menorrhagia with meclofenamate sodium

American Journal of Obstetrics and Gynecology
J M VargyasD R Mishell


A double-blind, placebo-controlled crossover trial was undertaken to determine the efficacy of meclofenamate sodium in the treatment of menorrhagia. Twenty-nine patients who had a baseline menstrual blood loss greater than 60 ml received 2 months' each of meclofenamate sodium, 100 mg by mouth, three times a day, or a placebo. The mean menstrual blood loss was reduced from 141.6 +/- 15.9 ml at baseline to 69.0 +/- 6.3 ml during treatment cycles but remained increased during placebo cycles (135.6 +/- 11.3 ml). The symptoms of dysmenorrhea, backache, and headache were significantly reduced only during active drug periods. The number of days of flow and pads or tampons used was also reduced during drug cycles but not during placebo cycles. Overall, 26 of the 29 patients evaluated had a reduction in menstrual blood loss with the use of meclofenamate sodium. It appears that many women with unexplained menorrhagia may benefit from this treatment.


Nov 1, 1979·Prostaglandins·M H Abel, R W Kelly
Oct 1, 1977·British Journal of Obstetrics and Gynaecology·P J HaynesA C Turnbull
May 1, 1976·British Journal of Obstetrics and Gynaecology·E A WillmanS G Clayton
Jan 1, 1971·Acta Obstetricia Et Gynecologica Scandinavica·E Guttorm
Oct 31, 1983·The American Journal of Medicine·D R Robinson
Jan 1, 1964·Scandinavian Journal of Clinical and Laboratory Investigation·L HALLBERG, L NILSSON


Aug 10, 2015·American Journal of Obstetrics and Gynecology·Linda D Bradley, Ndeye-Aicha Gueye
Dec 1, 1992·Baillière's Clinical Obstetrics and Gynaecology·Ian S Fraser
Mar 1, 1997·American Journal of Obstetrics and Gynecology·J A Spinnato
Sep 1, 1996·American Journal of Obstetrics and Gynecology·C J Chuong, P F Brenner
Jan 1, 1995·International Journal of Technology Assessment in Health Care·A CoulterM C Rees
Mar 21, 2007·Obstetrical & Gynecological Survey·Anita L Nelson, Stephanie B Teal
Mar 1, 1991·Advances in Contraception : the Official Journal of the Society for the Advancement of Contraception·M Barthwal, K Srivastava
Jan 1, 1989·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·C Benedetto
Sep 20, 2019·The Cochrane Database of Systematic Reviews·Magdalena Bofill RodriguezCindy Farquhar
Jan 19, 1999·Obstetrical & Gynecological Survey·S A StabinskyJ L Breen
Jan 26, 1999·Clinical Obstetrics and Gynecology·C M March
Feb 12, 2015·Obstetrical & Gynecological Survey·Johannes BitzerIan S Fraser
Feb 27, 2013·The Cochrane Database of Systematic Reviews·Anne LethabyCindy Farquhar
Jun 16, 1990·BMJ : British Medical Journal·A L Magos
Sep 1, 1990·Asia-Oceania Journal of Obstetrics and Gynaecology·V GroverS Kalra
Aug 6, 1995·Quality in Health Care : QHC·A CoulterT A Sheldon

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Nodding Syndrome

Nodding Syndrome is a neurological and epileptiform disorder characterized by psychomotor, mental, and growth retardation. Discover the latest research on Nodding Syndrome here.

LRRK2 & Microtubules

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease (PD). LRRK2 mutations in PD have been shown to enhance its association with microtubules. Here is the latest research.